StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0243.KL$0.21+2.44%
Fair $0.21+0.0%

0243.KL

Cengild Medical Berhad

Healthcare / Medical Care FacilitiesKuala Lumpur

$0.21

+0.00 (+2.44%)

Fairly Valued+0.0%Fair Value $0.21Fund rank 26/100 · Data gapFallback financials|
SA 44/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-2.8M · quality 43.7/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 19/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

44/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 0243.KLLocal privado en este navegador · Cengild Medical Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$175M

P/E

21.0x

↑

EV/EBITDA

8.5x

↓

ROE

9.7%

↑

Gross Margin

46.1%

↓

Debt/Equity

0.42

↑
52-Week Range$0
$0$0

TradingView lightweight chart

0243.KL price, volumen y niveles de valoración

Último $0.210Periodo -54.8%
Fair value: $0.210

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+7.5%

FCF CAGR

—

FCF margin

-26.5%

FCF / Net income

-1.92x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $80.0M · net income $11.1M · FCF $-21.2M

2022-FY → 2025-FY

Gross margin

46.1%+5.7% pts

Operating margin

18.5%+0.6% pts

Net margin

13.8%-0.8% pts

FCF margin

-26.5%-49.6% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$80.0M$80.0M$66.8M$70.3M$64.4M
Net Income$11.1M$11.1M$11.1M$13.3M$9.4M
EBITDA$24.9M$24.9M$21.3M$21.3M$17.4M
EPS0.010.010.010.020.01
Gross Margin46.1%46.1%46.5%43.7%40.4%
Operating Margin18.5%18.5%19.8%20.6%18.0%
Net Margin13.8%13.8%16.6%18.9%14.6%
Balance Sheet
Debt/Equity0.420.420.070.140.17
Current Ratio3.933.93———
Cash Flow
Free Cash Flow$-21.2M$-21.2M$-2.8M$11.8M$14.9M
Returns
ROE9.7%9.7%10.0%12.5%10.1%
Valuation
P/E21.0021.0024.0623.2927.05
EV/EBITDA8.468.4612.7915.2215.27
P/B1.531.532.402.922.74
Growth & Yield
Revenue Growth19.7%19.7%-4.9%9.1%—
EPS Growth0.0%0.0%-17.4%10.3%—
Dividend Yield3.1%3.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

11.9%

razonable

EPS terminal req.

$0.02

Spread vs growth

-11.9%

5Y implied EPS CAGR

11.1%

razonable

EPS terminal req.

$0.02

Spread vs growth

-11.1%

10Y implied EPS CAGR

10.6%

razonable

EPS terminal req.

$0.04

Spread vs growth

-10.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -12.9%

Total return

-12.9%

Start / end P/E

18.8x → 15.8x

EPS bridge

0.01 → 0.01

Residual

+0.0%

EPS growth+0.0%
Multiple rerating-16.0%
Dividend+3.1%
Residual / FX / buybacks / cross-term+0.0%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.